Catch up on the latest developments in multiple myeloma and other plasma cell dyscrasias from #EHA2026, with live social media coverage from the Multiple Myeloma Hub: multiplemyelomahub.com/medic… #MultipleMyeloma #myeloma #mmsm

CONGRESS | #EHA2026 | PRESENTATION Enrique Ocio presents final results from the phase I DREAMM-9 study evaluating the optimal dose and schedule of belantamab mafodotin plus bortezomib, lenalidomide, and dexamethasone (BVRd) for the treatment of transplant-ineligible NDMM (N = 118). The highest response rates were observed with Q6/8W dosing (ORR, 96%; ≥CR, 88%; MRD negativity, 54%). Within the Q6/8W cohorts, induction with belantamab mafodotin 1.9 mg/kg resulted in deeper responses than the 1.4 mg/kg dose (≥CR, 92% vs 83%). Extended dosing intervals were associated with fewer Grade ≥3 ocular AEs; 86% of first events resolved with Q6/8W dosing, and 100% resolved with Q9/12W and Q12W dosing. These data support the use of belantamab mafodotin 1.9 mg/kg Q8W for 24 weeks, followed by Q12W dosing, in the DREAMM-10 and PrE1005 studies. Follow our live feed for more updates: loom.ly/CXccZxs Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #MultipleMyeloma #myeloma #mmsm #MedEd

CONGRESS | #EHA2026 | PRESENTATION Binod Dhakal presents long-term follow-up results from the phase I CaMMouflage trial evaluating CB-011, an allogeneic anti-BCMA CAR T-cell therapy with immune cloaking, for the treatment of RRMM (N = 48). Among BCMA-naïve patients treated at the recommended expansion dose (450M CAR-T cells; n = 12), CB-011 demonstrated an ORR of 92% and a ≥CR rate of 83%. MRD negativity (10^-5) was observed in 91% of evaluable patients (n = 11). Grade ≥3 infections and CRS occurred in 25% and 8%, respectively. There were no instances of GvHD, IEC-EC, parkinsonism, or cranial nerve palsies. Enrolment in the dose-expansion portion is ongoing in both BCMA-naïve and BCMA-exposed patients. Follow our live feed for more updates: loom.ly/CXccZxs Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #MultipleMyeloma #myeloma #mmsm #MedEd @bhemato

It’s the final day! Catch up on the latest developments in multiple myeloma from the EHA2026 Congress, via our congress feed – available on the hub.

CONGRESS | #EHA2026 | PRESENTATION Meletios Dimopoulos presents results from the phase III SUCCESSOR-2 trial evaluating mezigdomide plus carfilzomib and dexamethasone (MeziKd) versus Kd for the treatment of RRMM. MeziKd was associated with improved PFS versus Kd, with a median PFS of 18.0 versus 8.3 months (HR, 0.48; p < 0.0001). ORR was 80.2% with MeziKd vs 53.4% with Kd, while ≥CR rates were 26.7% and 8.9%, respectively. Grade 3/4 TEAEs occurred in 83.7% and 56.5% of patients, respectively, with Grade 3/4 neutropenia reported in 61.1% and 9.1% of patients. Any-grade infections occurred in 72.9% and 53.8% of patients receiving MeziKd and Kd, respectively. Follow our live feed for more updates: loom.ly/CXccZxs Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #MultipleMyeloma #myeloma #mmsm #MedEd @thanosdimop

CONGRESS | #EHA2026 | PRESENTATION Peter Voorhees presents results from the phase III MonumenTAL-3 study evaluating talquetamab plus daratumumab ± pomalidomide (TalDP; TalD), versus daratumumab plus pomalidomide, and dexamethasone (DPd) for the treatment of RRMM. TalDP and TalD was associated with improved PFS vs DPd, corresponding to a reduced the risk of progression or death by 72% (HR, 0.28; P < 0.0001) and 67% (HR, 0.33; P < 0.0001), respectively. At 24 months, PFS rates were 81.3% with TalDP, 77.6% with TalD, and 51.2% with DPd. TalDp/TalD were also associated with higher ORR, ≥CR, and MRD-negative CR rates vs DPd. Safety findings were consistent with the known profiles of the individual agents. Follow our live feed for more updates: loom.ly/CXccZxs Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #MultipleMyeloma #myeloma #mmsm #MedEd

CONGRESS | #EHA2026 | PRESENTATION Prashant Kapoor presents results from the phase I/II IDEAL study evaluating iberdomide-based quadruplet therapy for NDMM (N = 44). The ORR was 100%. The CR rate increased from 43% at induction to 57% at deepest response, while the MRD-negative CR rate increased from 34% to 52%. At a median follow-up of 22.8 months, 12- and 18-month PFS rates were 92.0% and 88.9%, respectively, and 12- and 18-month OS rates were 97.4% and 94.5%. The most common Grade 3 and 4 TEAE was neutropenia (40.9% and 18.2%). 29.5% required G-CSF support. Follow our live feed for more updates: loom.ly/CXccZxs Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #MultipleMyeloma #myeloma #mmsm #MedEd

CONGRESS | #EHA2026 | PRESENTATION Rahul Banerjee presents results from an analysis of the phase III MajesTEC-3 study evaluating teclistamab plus daratumumab (Tec-Dara) in patients with RRMM, stratified by cytogenetic and functional risk. Tec-Dara improved PFS versus DPd/DVd across all cytogenetic and functional risk groups. In patients with prespecified HR cytogenetics, median PFS was not reached with Tec-Dara versus 14.4 months with DPd/DVd (HR, 0.15), while estimated 36-month PFS rates were 77.7% versus 11.5%, respectively. Tec-Dara also increased MRD-negative ≥CR rates across risk groups, including among patients with functional high-risk disease (42.9% vs 5.6% at 10⁻⁵sensitivity; OR, 12.75). Follow our live feed for more updates: loom.ly/CXccZxs Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #MultipleMyeloma #myeloma #mmsm #MedEd @RahulBanerjeeMD

CONGRESS | #EHA2026 | POSTER C. Ola Landgren, Sylvester Comprehensive Cancer Center, shares results from the phase 1b MagnetisMM-20 trial of elranatamab carfilzomib dexamethasone (EKd) in patients with R/RMM (N = 21). No DLTs were reported. All patients experienced TEAEs and SAEs occurred in 61.9% of patients. Hematologic TEAEs occurred in 71.4% of patients and infections occurred in 85.7% of patients. All CRS events were Grade 1/2 and no ICANS events were reported. The ORR was 95.2%, with a CR or better in 71.4% of patients. The median DoR, PFS, and OS were NR. Follow our live feed for more updates: loom.ly/CXccZxs Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #MultipleMyeloma #myeloma #mmsm #MedEd @SylvesterCancer @DrOlaLandgren

CONGRESS | #EHA2026 | PRESENTATION Niels van de Donk presents updated safety run-in results from the MajesTEC-4 study evaluating teclistamab ± lenalidomide versus lenalidomide alone as post-transplant maintenance for NDMM. Teclistamab-based maintenance was associated with grade 1/2 CRS events only and no cases of ICANS. During maintenance, ≥CR rates were 96.7–100% across cohorts, with MRD-negative CR rates at 12 months of 90–100% among evaluable patients. Median PFS was not reached in any cohort, with estimated 24-month PFS rates of 94–96.6%. Follow our live feed for more updates: loom.ly/CXccZxs Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #MultipleMyeloma #myeloma #mmsm #MedEd @amsterdamumc

CONGRESS | #EHA2026 | PRESENTATION Saad Usmani presents the final results from the phase III CEPHEUS study evaluating daratumumab plus bortezomib, lenalidomide, and dexamethasone (D-VRd) vs VRd in TI-NDMM. After a median follow-up of 76 months, D-VRd was associated with higher rates of MRD negativity than VRd, including 61.1% vs 40.0% at 10⁻⁵ (OR, 2,35; p = 0.0004) and 46.5% vs 27.6% at 10⁻⁶ (OR, 2.27; p = 0.001). D-VRd also reduced the risk of progression or death by 45% versus VRd (HR, 0.55; p = 0.0007). No additional safety concerns were identified with longer follow-up. Follow our live feed for more updates: loom.ly/CXccZxs Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #MultipleMyeloma #myeloma #mmsm #MedEd

CONGRESS | #EHA2026 | PRESENTATION Cyrille Touzeau presents results from the phase III MajesTEC-9 study evaluating teclistamab monotherapy versus pomalidomide, bortezomib, and dexamethasone (PVd) or carfilzomib and dexamethasone (Kd) in patients with RRMM. After a median follow-up of 17.3 months, median PFS was not reached with teclistamab versus 8.2 months with PVd/Kd (HR, 0.29; p < 0.0001). ORR was higher with teclistamab versus PVd/Kd (OR, 4.62; p < 0.0001). OS also favored teclistamab (HR, 0.60; p = 0.002). Infection rates were higher with teclistamab, including grade 5 infections (5.5% vs 2.8% with PVd/Kd). Follow our live feed for more updates: loom.ly/CXccZxs Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #MultipleMyeloma #myeloma #mmsm #MedEd @CHUnantes

CONGRESS | #EHA2026 | POSTER Tim Richardson, University of Cologne, shares insights into transitioning cilta-cel administration to the outpatient setting for the treatment of MM (N = 12). Overall, 33.3% of patients required short-term inpatient admission within 30 days of treatment, with a median stay of 3 days. At a median follow-up of 9.9 months, Grade 1 and 2 CRS occurred in 66.7% and 8.3% of patients, respectively; no Grade ≥3 CRS occurred. The CRR was 91.7%. Follow our live feed for more updates: loom.ly/CXccZxs Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #MultipleMyeloma #myeloma #mmsm #MedEd @UniCologne

CONGRESS | #EHA2026 | POSTER Wanyan Ouyang, Ruijin Hospital-Shanghai Jiao Tong University School of Medicine, shares a multicenter experience of real-world outcomes with zevorcabtagene autoleucel in patients with MM (N = 136). The ORR was 90.8%, with a CR or better in 68.3% of patients. Among patients with prior BCMA-targeted therapy and GPRC5D CAR T-cell therapy exposure (n = 9), the ORR was 77.8%. The ORRs in patients with and without high-risk cytogenetics were 87.8% and 94.0%, respectively. The most common TRAE was cytopenia. Any grade CRS and ICANS occurred in 73.3% and 5.8% of patients, respectively. Follow our live feed for more updates: loom.ly/CXccZxs Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #MultipleMyeloma #myeloma #mmsm #MedEd @sjtu1896

CONGRESS | #EHA2026 | POSTER Cesar Rodriquez Valdas, Mount Sinai Hospital, presents real-world evidence from a large US cancer center for outpatient step-up dosing (SUD) of teclistamab or talquetamab with prophylactic tocilizumab in patients with R/R MM (N = 54). Patients either received hybrid SUD with tocilizumab to treat CRS (HY) or fully outpatient SUD with prophylactic tocilizumab (OP-toci). All patients in the OP-toci group completed SUD, while all but one completed SU in the HY group. CRS within 14 days post-index was more common in the HY group, particularly with talquetamab, than the OP-toci group. All CRS and ICANS events were Grade 1. Healthcare resource utilization was lower in patients receiving OP-toci than HY. Follow our live feed for more updates: loom.ly/CXccZxs Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #MultipleMyeloma #myeloma #mmsm #MedEd @MountSinaiNYC @myelomatips

CONGRESS | #EHA2026 | POSTER Johannes Waldschmidt, University of Würzberg Medical Center, presents real world evidence from two nationwide compassionate-use programs of belantamab mafodotin-based combination therapy in patients with MM (N = 60). The ORR in target patients was 71.0%, with a CBR of 74.2%. Among patients with prior BCMA exposure, the ORR and CBR rates were 26.3% and 42.1%, respectively, and were 63.4% and 73.2% in BCMA-naïve patients. The median PFS and OS across all patients were 9.9 months and 26.1 months, respectively. Prior BCMA exposure reduced median PFS to 3.4 months. Follow our live feed for more updates: loom.ly/CXccZxs Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #MultipleMyeloma #myeloma #mmsm #MedEd @Uni_WUE

CONGRESS | #EHA2026 | POSTER Anna Sureda, Institut Català d’Oncologia-Hospitalet and Universitat de Barcelona, presents findings from a subgroup analysis, by renal function, of the CC-220-MM-001 trial of iberdomide daratumumab dexamethasone in patients with ND MM (N = 75). The median follow-up was 22.3 months. The best ORRs were 90.0%, 93.1%, and 97.1% in patients with no, mild, and moderate RI, with ≥CR rates of 80.0%, 55.2%, and 74.3%, respectively. MRD-negativity rates at any time were 80.0%, 48.3%, and 71.4%, respectively, and the median DoR was NR in any subgroup. Grade 3/4 TEAEs occurred in 100% of patients with no or mild RI and 94.3% of patients with moderate RI. Follow our live feed for more updates: loom.ly/CXccZxs Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #MultipleMyeloma #myeloma #mmsm #MedEd @UniBarcelona @AnnaSureda5

CONGRESS | #EHA2026 | POSTER Shaji Kumar, Mayo Clinic, shares expansion results from the CAMMA 2 study of cevostamab in patients with R/R MM who have received prior BCMA-targeted CAR T-cell therapy (N = 41). The ORR was 43.9%, with a VGPR or better in 34.1% of patients. The median DoR was 17.4 months. All patients experienced ≥1 AE, and SAEs were reported in 68.3% of patients. CRS was the most common AE (75.6%); all CRS events were Grade 1 or 2 and were managed with tocilizumab or steroids. Follow our live feed for more updates: loom.ly/CXccZxs Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #MultipleMyeloma #myeloma #mmsm #MedEd @myelomaMD @MayoClinic

CONGRESS | #EHA2026 | POSTER María-Victoria Mateos, University Hospital of Salamanca, presents real-world outcomes in patients with smoldering MM from the SPARK study (N = 373). The median follow-up was 53.1 months. Overall, 44.5% of patients had a PFS event, with 37.3% of patients progressing to MM. The median OS was NR and the median PFS was 58.4 months. Regardless of how high-risk smoldering MM was defined, >50% of progressions to MM were CRAB events and >50% included organ damage. Follow our live feed for more updates: loom.ly/CXccZxs Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #MultipleMyeloma #myeloma #mmsm #MedEd @mvmateos

Day 3 of EHA2026 is here. Still catching up? Head over to the Multiple Myeloma Hub congress feed to revisit all our live coverage from the past few days.

CONGRESS | #EHA2026 | PRESENTATION Efstathios Kastritis presents phase I dose-escalation safety and efficacy data for etentamig for relapsed/refractory AL amyloidosis. The 40 mg dose was selected for phase II dose-expansion. At the 40 mg dose, the hematologic CR rate was 100%, with no cases of hematologic progression reported. Median time to iFLC <10 mg/L was 7 days, and cardiac and renal response rates were 83% and 50%, respectively. There were no cases of CRS or ICANS, and no AE-related discontinuations were reported at the 40 mg dose level. Follow our live feed for more updates: loom.ly/CXccZxs Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #Amyloidosis #ALAmyloidosis #MedEd @uoaofficial